scorecardresearch
Add as a preferred source on Google
Sunday, November 30, 2025
TopicVaccine

Topic: Vaccine

Moderna shares fall from all-time high as euphoria around Covid vaccine data wears off

Moderna's shares, which nearly made an MIT professor a billionaire, began to slide after a report from the health publication Stat highlighted the early nature of the vaccine data.

Moderna’s clinical trial raises Covid vaccine hope, and a look at other potential vaccines

In episode 474 of #CutTheClutter, Shekhar Gupta looks at the potential Covid-19 vaccines being developed across the world.

MIT professor’s stake in biotech firm Moderna Inc on brink of topping $1 billion

Bob Langer’s 3.2% holding rose to $934.3 million Monday after the firm reported encouraging early trial results for an experimental Covid-19 vaccine.

Vaccine developers like Moderna need to take their time

Moderna announced the first reported data from human trials. That’s good news, but the project ahead will be harder to accomplish with speed.

Speed, reach, efficacy: How 3 challenges to creating a corona vaccine are being overcome

The coronavirus vaccine needs to be available in all parts of the world to ensure that a reservoir of the virus does not remain. Work is going on in record time to achieve that.

Eradicating Covid-19 might justify risky vaccine trials

The idea of infecting healthy subjects with Covid-19 might strike as repellent, yet many scientists and policy makers say it’s worth thinking about.

Every scientific success is built on a history of failures, Covid-19’s cure could be too

In science, establishing that something doesn’t work is as crucial as finding a solution. This is why most Covid-19 clinical trials are repurposing existing drugs.

We can eradicate novel coronavirus with a vaccine, as we did with smallpox

A coronavirus vaccine is within our reach, with more than 90 under development and trials, and it is our best hope to stem transmission and generate herd immunity.

French drugmaker Sanofi sparks outrage after CEO says US could be first to get vaccine

Sanofi’s CEO said the US is likely to be first in line if the company succeeds in creating a Covid vaccine since it was the first to fund its research.

We will likely need several vaccines to combat coronavirus across the world

US National Institutes of Health director says the first people to get a vaccine will likely be frontline health workers and those with chronic conditions.

On Camera

‘Delhi winters’ is a legend. Now it’s just air anxiety

The wealthy float above the crisis—insulated in air-purified cars, weekend getaways at farmhouses, and vacations timed perfectly to coincide with Delhi’s worst weeks.

Karnataka startups feel the chill as global funding winter sets in. Fintech emerges as sole bright spot

The state raises just $2.7 billion in first nine months of 2025 compared to $4.5 billion last year, with late-stage investments hit hardest.

What’s expected from Putin’s India visit in December—Defence Secretary explains

ThePrint had previously reported that India & Russia are talking about 5 more regiments of the S-400, but no contracts are to be signed during the Russian president's visit.

Gaali cricket: Bavuma stands tall, India’s Test ego cut to size

The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.